| abstract |
Described herein as Brutin's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3, A pharmaceutical formulation of 4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of treating an autoimmune disease or condition, a xenon immune disease or condition, a cancer comprising lymphoma, and an inflammatory disease or condition, alone or in combination with other therapeutic agents. |